Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia

Discovery of Marinopyrrole A (Maritoclax) as a Selective Mcl-1 Antagonist that Overcomes ABT-737 Resistance by Binding to and Targeting Mcl-1 for Proteasomal Degradation

“…The chemical shifts for all assigned residues at each titration point were tabulated and the average differences between the chemical shifts of apo Mcl-1 and the chemical shifts observed after the final addition of maritoclax were determined using the following relationship: Average Chemical Shift Change ϭ ((DH Cell Culture and Transfection-K562, Raji, HL60, HL60/ VCR, Jurkat, and Jurkat⌬Bak cell lines were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and 100 units/ml penicillin, 100 g/ml streptomycin, 0.25 g/ml amphotericin B (Cellgro) at 37°C and 5% CO 2 . Primary largegranular lymphocyte leukemia (LGLL) cells were obtained from LGLL patients as previously described (31) and an informed consent was signed for sample collection according to a protocol approved by the Institutional Review Board of Penn State Hershey Cancer Institute. Patients received no treatment at the time of sample acquisition.…”

Allergy and risk of hematologic malignancies: Associations and mechanisms

“…Multiple cell survival pathways, including JAK2/STAT3, sphingolipid signaling, RAS/MEK/ERK, and SFK/PI3K/Akt, have been found to be constitutively activated in LGL leukemia patients. A system biology approach identified IL-15 and PDGF as master survival signaling switches that may have a deep effect on all known deregulations in T-LGL leukemia [47][48][49][50][51][52][53][54][55].…”

Large granular lymphocyte leukemia: clinical background, molecular pathogenesis and treatment

“…However, it is also possible to use syngeneic RNK16 (rat-derived LGL leukemia cell line) cells to accelerate this process. In this disease model, the rats emulate human aggressive disease and demonstrate splenomegaly, lymphocytosis and bone marrow invasion [68]. However, both of these models do not use human LGLs.…”